Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aref Al-Kali

Showing results (11-20 of 148) with videos related to

Pageof 15
Sort By:
American Journal of Hematology|November 9, 2022
Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survivalNaseema Gangat, Kebede H Begna, Aref Al-Kali, et al.
American Journal of Hematology|May 6, 2017
Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experienceRama Nanah, Kristen McCullough, William Hogan, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 21, 2015
Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up ExperienceSalih Subari, Mrinal Patnaik, Dima Alfakara, et al.
Oncotarget|July 13, 2014
A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesisNa Shen, Fei Yan, Jiuxia Pang, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 17, 2014
Monosomal karyotype predicts adverse prognosis in patients diagnosed with chronic myelomonocytic leukemia: a single-institution experienceAysha Alsahlawi, Hassan Alkhateeb, Mrinal Patnaik, et al.
International Journal of Hematology|January 20, 2016
Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapySalih Subari, Firas Baidoun, Muhanad Hreh, et al.
ACS Applied Materials & Interfaces|April 19, 2018
HDL-AuNPs-BMS Nanoparticle Conjugates as Molecularly Targeted Therapy for LeukemiaNa Shen, Fei Yan, Jiuxia Pang, et al.
Anticancer Research|July 5, 2020
Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-grade Myelodysplastic SyndromesHassan B Alkhateeb, Mrinal M Patnaik, Aref Al-Kali, et al.
British Journal of Haematology|December 17, 2014
Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosisRamy A Abdelrahman, Kebede H Begna, Aref Al-Kali, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 6, 2011
Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemiaAref Al-Kali, Jorge Cortes, Stefan Faderl, et al.
Pageof 15

Showing results (11-20 of 148) with videos related to

Sort By:
Pageof 15
American Journal of Hematology|November 9, 2022
Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survivalNaseema Gangat, Kebede H Begna, Aref Al-Kali, et al.
American Journal of Hematology|May 6, 2017
Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experienceRama Nanah, Kristen McCullough, William Hogan, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 21, 2015
Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up ExperienceSalih Subari, Mrinal Patnaik, Dima Alfakara, et al.
Oncotarget|July 13, 2014
A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesisNa Shen, Fei Yan, Jiuxia Pang, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 17, 2014
Monosomal karyotype predicts adverse prognosis in patients diagnosed with chronic myelomonocytic leukemia: a single-institution experienceAysha Alsahlawi, Hassan Alkhateeb, Mrinal Patnaik, et al.
International Journal of Hematology|January 20, 2016
Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapySalih Subari, Firas Baidoun, Muhanad Hreh, et al.
ACS Applied Materials & Interfaces|April 19, 2018
HDL-AuNPs-BMS Nanoparticle Conjugates as Molecularly Targeted Therapy for LeukemiaNa Shen, Fei Yan, Jiuxia Pang, et al.
Anticancer Research|July 5, 2020
Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-grade Myelodysplastic SyndromesHassan B Alkhateeb, Mrinal M Patnaik, Aref Al-Kali, et al.
British Journal of Haematology|December 17, 2014
Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosisRamy A Abdelrahman, Kebede H Begna, Aref Al-Kali, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 6, 2011
Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemiaAref Al-Kali, Jorge Cortes, Stefan Faderl, et al.
Pageof 15